The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered

The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered

Bibliographic Details
Main Authors: Peter Borchmann, Alexander Fosså, Monika Długosz-Danecka, Boris Böll, Markus Dietlein, Carsten Kobe, Helen Goergen, Andreas Engert
Format: Article
Language:English
Published: Wolters Kluwer 2018-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000052
id doaj-85edf5fba5ed4e7e9bd974972f7a1d07
record_format Article
spelling doaj-85edf5fba5ed4e7e9bd974972f7a1d072020-11-25T03:44:46ZengWolters KluwerHemaSphere2572-92412018-06-012310.1097/HS9.0000000000000052201806000-00005The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions UnansweredPeter BorchmannAlexander FossåMonika Długosz-DaneckaBoris BöllMarkus DietleinCarsten KobeHelen GoergenAndreas Engerthttp://journals.lww.com/10.1097/HS9.0000000000000052
collection DOAJ
language English
format Article
sources DOAJ
author Peter Borchmann
Alexander Fosså
Monika Długosz-Danecka
Boris Böll
Markus Dietlein
Carsten Kobe
Helen Goergen
Andreas Engert
spellingShingle Peter Borchmann
Alexander Fosså
Monika Długosz-Danecka
Boris Böll
Markus Dietlein
Carsten Kobe
Helen Goergen
Andreas Engert
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
HemaSphere
author_facet Peter Borchmann
Alexander Fosså
Monika Długosz-Danecka
Boris Böll
Markus Dietlein
Carsten Kobe
Helen Goergen
Andreas Engert
author_sort Peter Borchmann
title The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
title_short The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
title_full The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
title_fullStr The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
title_full_unstemmed The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
title_sort phase 3 study echelon-1 evaluating brentuximab vedotin in patients with newly diagnosed hodgkin lymphoma leaves important questions unanswered
publisher Wolters Kluwer
series HemaSphere
issn 2572-9241
publishDate 2018-06-01
url http://journals.lww.com/10.1097/HS9.0000000000000052
work_keys_str_mv AT peterborchmann thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT alexanderfossa thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT monikadługoszdanecka thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT borisboll thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT markusdietlein thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT carstenkobe thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT helengoergen thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT andreasengert thephase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT peterborchmann phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT alexanderfossa phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT monikadługoszdanecka phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT borisboll phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT markusdietlein phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT carstenkobe phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT helengoergen phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
AT andreasengert phase3studyechelon1evaluatingbrentuximabvedotininpatientswithnewlydiagnosedhodgkinlymphomaleavesimportantquestionsunanswered
_version_ 1724512834545516544

Similar Items